Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximabHubert Piessevaux, Marc Buyse, Michael Schlichting, et al.
Health and Quality of Life Outcomes|March 29, 2019
Correction to: Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinomaMurtuza Bharmal, Fatoumata Fofana, Carla Dias Barbosa, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 10, 2021
How Assessment-Schedule Matching Limits Bias When Comparing Progression-Free Survival in Single-Arm Studies: An Application in Second-Line Urothelial Carcinoma TreatmentsVenediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, et al.
Health and Quality of Life Outcomes|December 24, 2017
Psychometric properties of the FACT-M questionnaire in patients with Merkel cell carcinomaMurtuza Bharmal, Fatoumata Fofana, Carla Dias Barbosa, et al.
Clinical Colorectal Cancer|December 28, 2013
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE studyJean-Yves Douillard, Tomasz Zemelka, George Fountzilas, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2012
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCarsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 1, 2022
Is IQWiG's 15% Threshold Universally Applicable in Assessing the Clinical Relevance of Patient-Reported Outcomes Changes? An ISPOR Special Interest Group ReportMichael Schlichting, Michael Hennig, Katja Rudell, et al.
Pharmacoeconomics|September 27, 2019
Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer StudiesVenediktos Kapetanakis, Thibaud Prawitz, Michael Schlichting, et al.
European Radiology|May 13, 2014
Evaluating the agreement between tumour volumetry and the estimated volumes of tumour lesions using an algorithmRuediger P Laubender, Julia Lynghjem, Melvin D'Anastasi, et al.
Future Oncology (London, England)|May 19, 2025
Cost-effectiveness of cetuximab-containing regimens for squamous cell carcinoma of the head and neck in ItalyPhilipp Ivanyi, Ash Bullement, Andrea Botticelli, et al.
Pageof 4